- Home
- VYNE vs AEON Comparison
VYNE vs AEON Comparison
Compare VYNE & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VYNE | AEON |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 19.0M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | VYNE | AEON |
|---|---|---|
| Price | $0.65 | $0.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 117.5K | 28.0K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.51 |
| 52 Week High | $1.72 | $1.45 |
Technical Indicators
Market Signals| Indicator | VYNE | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 50.18 |
| Support Level | $0.62 | $0.70 |
| Resistance Level | $0.69 | $0.75 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 60.45 | 95.87 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.